← All trials
NCT05112159
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 27, 2021
- Primary completion
- May 18, 2022
- Completion date
- Jul 30, 2022
- First posted
- Nov 8, 2021
- Last posted
- Nov 8, 2021
- Enrollment
- 46
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Nanjing Immunophage Biotech Co., LtdLead sponsor
- Nanjing Immunophage Biotech Co., LtdStudy director
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.